Questions: Opioid Use Disorder

Question 1

A person with opioid use disorder has been abstinent for three months. They relapse and take the same dose they used regularly before stopping. They are at high risk of fatal overdose. The most accurate explanation is:

• A. Their liver has lost opioid-metabolizing enzymes during abstinence, causing the drug to accumulate to toxic levels
• B. Three months of abstinence produces psychological hypersensitivity that amplifies drug effects
• C. Tolerance to respiratory depression is lost during abstinence while their habitual dose expectation has not reset, creating a fatal mismatch
• D. After abstinence, opioid receptors are dramatically upregulated, causing the drug to bind with much greater affinity

Answer: (C)

This is the key clinical mechanism behind overdose deaths in people who have been abstinent. Tolerance to euphoria and sedation develops quickly and is lost relatively slowly; tolerance to respiratory depression develops more slowly but is lost faster during abstinence. A person who takes their pre-abstinence dose after a period of not using has a partially reset respiratory system that can no longer handle a dose calibrated to a tolerant state. The dose that once produced manageable sedation now causes fatal respiratory depression.

Question 2

During opioid withdrawal, symptoms including pain hypersensitivity, anxiety, and intense craving occur primarily because:

• A. Opioid metabolites accumulate in tissues during chronic use and release toxic signals during withdrawal
• B. The brain's opioid system, which has downregulated to compensate for chronic drug presence, is now underactivated in the absence of exogenous opioids
• C. Withdrawal is primarily a conditioned psychological response driven by environmental cues associated with past drug use
• D. The immune system mounts an inflammatory response against opioid metabolites during cessation

Answer: (B)

With chronic opioid exposure, the brain adapts through receptor downregulation and desensitization — fewer opioid receptors are expressed and those remaining are less responsive — to maintain homeostasis. When exogenous opioids are removed, the compensatory adaptations are unmasked: the endogenous opioid system is now insufficient to maintain baseline function in a system calibrated around drug presence. The result is rebound hyperactivation of pain pathways, stress systems, and autonomic circuits — withdrawal symptoms are the signature of that homeostatic recalibration being reversed.

Question 3

Opioid withdrawal symptoms, while extremely uncomfortable, reflect a moral failure or weakness of willpower in people with opioid use disorder.

• T. True
• F. False

Answer: False

Withdrawal is the predictable physiological consequence of receptor downregulation and desensitization following chronic opioid exposure. When a biological system has adapted to the chronic presence of a drug — reducing receptor density and coupling efficiency to maintain homeostasis — the sudden absence of that drug produces rebound effects. This process occurs regardless of motivation, character, or willpower. Framing withdrawal as moral failure misunderstands the biology and is clinically harmful — it can deter people from seeking treatment and undermine evidence-based approaches.

Question 4

Naloxone reverses opioid overdose by accelerating the breakdown and elimination of opioids from the bloodstream.

• T. True
• F. False

Answer: False

Naloxone is a competitive μ-opioid receptor antagonist. It works by binding to μ-receptors with high affinity and displacing opioid agonists, blocking their effects at the receptor level. It does not affect blood opioid concentrations, drug metabolism, or elimination. By occupying the receptor without activating it, naloxone rapidly reverses respiratory depression — but its duration of action (30–90 minutes) is shorter than many opioids, so repeated dosing may be needed to prevent re-narcotization as the naloxone is cleared.

Question 5

Why is the differential rate of tolerance development between respiratory depression and euphoria/sedation clinically dangerous, and how does buprenorphine reduce this risk?

Model answer: Tolerance to euphoria and sedation develops faster than tolerance to respiratory depression, and respiratory tolerance is also lost faster during abstinence. Someone returning to their prior dose after a period of abstinence can fatally overdose because their respiratory sensitivity has partially reset while their dose expectation has not. Buprenorphine, as a partial agonist with a ceiling effect on respiratory depression, maintains stable partial receptor occupancy without the dangerous peaks of full agonists.

This asymmetric tolerance profile is the direct pharmacological mechanism behind the epidemic of overdose deaths among people re-entering opioid use after periods of incarceration, hospitalization, or treatment. Buprenorphine's partial agonism means it occupies receptors and prevents withdrawal/craving, but cannot produce the deep respiratory depression that a full agonist can — even at high doses, its respiratory effect plateaus. Methadone (a full agonist with a very long half-life) works differently: its steady-state blood level prevents the peaks and troughs of short-acting opioids, eliminating the abuse pattern rather than capping the ceiling effect.